SALTIRE 2005

1 Treatments

**Studied treatment**  atorvastatin 80mg daily

**Control treatment**  placebo

**Concomittant treatments**  -

2 Patients

**Patients**  patients with calcific aortic stenosis

**Inclusion criteria**  older than 18 years of age; calcific aortic stenosis; aortic-jet velocity of at least 2.5 m per second; aortic-valve calcification on echocardiography

**Exclusion criteria**  child-bearing potential without contraception; active or chronic liver disease; history of alcohol or drug abuse; severe mitral-valve stenosis (mitral-valve area, <1 cm²); severe mitral or aortic regurgitation; left ventricular dysfunction (ejection fraction, <35%); planned aortic-valve replacement; intolerance of statins; statin therapy or a potential benefit from statin therapy (according to the treating physician); baseline serum total cholesterol concentration of less than 150 mg per deciliter (4.0 mmol per liter); presence of a permanent pacemaker or cardiofibrillator

3 Methods

**Blinding**  double blind

**Design**  Parallel groups

**Centers**  -

**Geographical area**  -

**Sizes**  77/78

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death from any cause</td>
<td>3/77</td>
<td>5/78</td>
<td>0,61</td>
<td>[0,14; 2,64]</td>
</tr>
<tr>
<td>Hospitalization for severe aortic stenosis</td>
<td>3/77</td>
<td>5/78</td>
<td>0,61</td>
<td>[0,14; 2,64]</td>
</tr>
<tr>
<td>CV death, aortic replacement, hospitalization for severe aortic stenosis</td>
<td>13/77</td>
<td>21/78</td>
<td>0,63</td>
<td>[0,29; 1,37]</td>
</tr>
<tr>
<td>CV death</td>
<td>3/77</td>
<td>3/78</td>
<td>1,01</td>
<td>[0,20; 5,18]</td>
</tr>
<tr>
<td>Aortic-valve replacement</td>
<td>11/77</td>
<td>19/78</td>
<td>0,59</td>
<td>[0,26; 1,33]</td>
</tr>
</tbody>
</table>
5 References